Renalytix AI’s KidneyIntelX Gains Medicare Coverage Approval
Company Announcements

Renalytix AI’s KidneyIntelX Gains Medicare Coverage Approval

Renalytix AI (RNLX) just unveiled an announcement.

Renalytix plc announced a significant milestone as Medicare issued its final coverage determination for the company’s innovative product, kidneyintelX.dkd. This breakthrough could impact investors and market-watchers, highlighting a potential growth avenue for Renalytix amidst the healthcare sector’s evolving landscape.

See more data about RNLX stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyRenalytix announces collaboration with Steno Diabetes Center
GlobeNewswireRenalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US
GlobeNewswireRenalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!